Changing how we live with cancerDonate Today!
29 Bayswater Avenue
Ottawa, Ontario K1Y 2E5View Location Map
Is 3D Mammography more effective in detecting breast cancer?
The Ottawa Hospital Breast Health Centre and Ottawa Integrative Cancer Centre collaborate on clinical trial for breast cancer screening with digital breast tomosynthesis.
Researchers from The Ottawa Hospital Breast Health Centre and the Ottawa Integrative Cancer Centre (OICC) have opened the Ottawa site of the Lead-In to the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). The Breast Health Centre is one of three clinical trial sites to launch the Lead-In in Canada. It is expected that shortly this trial will be integrated into a larger U.S./Canada TMIST, managed by the ECOG-ACRIN Cooperative Clinical Trials Group.
TMIST is the first large randomized, multi-centre study to assess whether a novel “3D” digital tomosynthesis technology combined with 2D digital mammography may be more effective at reducing the incidence of advanced breast cancers than conventional 2D mammography alone. Previous smaller studies suggest that this new kind of mammography can increase breast cancer detection and reduce the rate of false positives and recalls for women who do not have cancer. If successful, implementation of this technology would provide greater assurance of an effective test, reduce patient stress and anxiety, and ultimately reduce costs to the health-care system. The current Lead-In study aims to enroll 6,300 women in Canada, including 2,000 from Ottawa. Women attending mammographic screening at the Breast Health Centre may be approached to participate.